Genmab Grants Stock Units and Warrants to Employees
Ticker: GNMSF · Form: 6-K · Filed: Sep 26, 2025 · CIK: 1434265
| Field | Detail |
|---|---|
| Company | Genmab A/S (GNMSF) |
| Form Type | 6-K |
| Filed Date | Sep 26, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: employee-compensation, equity-awards, stock-options
Related Tickers: GMAB
TL;DR
Genmab issued stock options and RSUs to employees on Sept 26, 2025.
AI Summary
On September 26, 2025, Genmab A/S announced the grant of restricted stock units and warrants to employees. This filing is a Form 6-K report for the month of September 2025, and it will be incorporated by reference into Genmab's existing S-8 registration statements.
Why It Matters
This announcement details employee compensation and potential future share dilution, which can impact investor sentiment and stock valuation.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of employee compensation and does not indicate any significant financial or operational changes.
Key Players & Entities
- Genmab A/S (company) — Registrant
- September 26, 2025 (date) — Date of Company Announcement
- Form 6-K (document) — Filing type
- S-8 registration statements (document) — Incorporated by reference
FAQ
What type of equity awards were granted by Genmab?
Genmab granted restricted stock units and warrants to employees.
What is the filing date of this Form 6-K?
This Form 6-K was filed as of September 26, 2025.
What is the purpose of this Form 6-K filing?
This Form 6-K is a report of a foreign private issuer for the month of September 2025, containing a company announcement regarding employee equity grants.
In which Genmab registration statements will this Form 6-K be incorporated by reference?
This Form 6-K will be incorporated by reference into Genmab A/S's registration statements on Form S-8 (File Nos. 333-232693, 333-253519, 333-262970, 333-277273 and 333-284876).
What is the principal executive office address for Genmab?
The address of Genmab's principal executive offices is Carl Jacobsens Vej 30, 2500 Valby, Denmark.
Filing Stats: 225 words · 1 min read · ~1 pages · Grade level 14.8 · Accepted 2025-09-25 19:16:33
Filing Documents
- gmab_20250925xx6k.htm (6-K) — 13KB
- gmab_20250925xx99d1.htm (EX-99.1) — 20KB
- genmab_logo.jpg (GRAPHIC) — 56KB
- 0001434265-25-000080.txt ( ) — 108KB
From the Filing
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF SEPTEMBER 2025 COMMISSION FILE NUMBER 001-38976 Genmab AS (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F This report on Form 6-K shall be deemed to be incorporated by reference in Genmab AS's registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970, 333-277273 and 333-284876 ) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. EXHIBIT INDEX Exhibit Description of Exhibit 99.1 Company Announcement Dated September 26, 2025 Grant of Restricted Stock Units and Warrants to Employees in Genmab SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. GENMAB AS BY s Anthony Pagano Name Anthony Pagano Title Executive Vice President Chief Financial Officer DATE SEPTEMBER 26, 2025